Nvidia Nears Record, RXO Jumps 24% on $5.8B C.H. Robinson Bid, Vaxcyte Surges 31%: Monday's Midday Market Movers

By midday Monday, Wall Street had settled into its favorite October posture: let the winners run. According to Barron's midday market update, stocks pushed higher as tech and communication names did the heavy lifting, even while rising bond yields kept leaning on the broader market. It was a split-screen session — the kind where the index says "fine" and the individual stories say "wild." Consider this your midday update on the morning open: the Nasdaq's fresh intraday record is still standing, but the afternoon belongs to the movers. Our morning piece has the open's setup.

The headliner, as usual, is Nvidia. Barron's reported Monday that the stock rose 1.5% to $237.67 by midday, putting it on pace to eclipse its all-time closing high of $235.74 set back in May. That number matters less than what it represents: the market's favorite stock reclaiming its crown at the exact moment everyone from Morgan Stanley to the power grid is asking whether the AI buildout can keep feeding itself. Nvidia is the trade that ate the market, and on Monday the trade was eating well.

The AI story has a new wrinkle this week, and it's worth your attention: Morgan Stanley's latest note argues Nvidia and Broadcom are shielded from the AI power crunch — but the rest of the chip chain isn't. Read that alongside Monday's tape and the picture gets sharper. Nvidia isn't just rising on vibes; it's rising because the analysts who were skeptical about AI infrastructure are now drawing a circle around exactly two companies that can't lose. That's a powerful bid.

Then there was PTC, which did the single most dramatic thing on the board. Barron's midday tape had the industrial software maker surging 34% to $192.71 after Schneider Electric agreed to buy it for $205 a share — a $22.6 billion all-cash deal. We covered that takeover in depth this morning, so here's the midday read: the market's verdict is that software with real industrial customers is worth a fat premium, and Schneider came in well above Friday's close to prove it. Full details on the Schneider-PTC deal here.

The other big M&A story rolled in on eighteen wheels. Reuters reported Monday that RXO jumped 24% after C.H. Robinson said it would acquire the freight-and-logistics company for an implied $5.8 billion in a stock-and-cash deal expected to close in the first half of 2027. The terms, per Reuters: RXO shareholders get $17.25 in cash plus 0.0856 C.H. Robinson shares for each RXO share — $30.25 a share all-in, a 29% premium to Friday's close. The combined company would carry an enterprise value north of $25 billion, with RXO holders owning about 11% of it. C.H. Robinson is promising $300 million in net run-rate cost synergies within two years, mostly by running RXO through its "Lean AI" operating model.

The market's reaction told both sides of the story. Per Barron's midday update, RXO soared while C.H. Robinson sank 9.7% — the classic acquirer's haircut, investors pricing in integration risk on day one. It's the oldest ritual on Wall Street: the buyer pays, the target pops, and the buyer's shareholders grumble about it over lunch. Whether the grumbling is right depends on whether those $300 million in synergies are real. Truck brokerage is a scale game, and this deal — if it closes — makes C.H. Robinson the undisputed heavyweight.

Monday's moonshot, though, belonged to biotech. Reuters reported that Vaxcyte surged 31% after its lead vaccine candidate, VAX-31, hit its primary endpoints in a late-stage Phase 3 trial in adults 50 and older. The data, per Reuters: immune responses at least comparable to Pfizer's Prevnar 20 and Merck's Capvaxive across the 28 bacterial strains shared with either rival — plus stronger responses against three strains unique to VAX-31 and against strain 20B. Safety looked clean, with no serious adverse events considered related to the vaccine. Vaxcyte now expects two more late-stage readouts in the first half of 2027 and plans to file for U.S. marketing approval in the first half of 2028.

Here's why the market cared so much: pneumococcal vaccines are a multi-billion-dollar franchise, and the incumbents felt the draft immediately — according to Barron's, Pfizer fell 1.5% and Merck 2.9%. Jefferies analyst Roger Song called the readout a "blue-sky" case, arguing VAX-31 could take significant share of an adult market that could reach $3 billion to $6 billion-plus. For scale, Pfizer's Prevnar family generated nearly $6.5 billion last year — its second-biggest product behind Eliquis, per Barron's. A small company just told two of the biggest drugmakers on earth that it wants their lunch money, and the market believed it. That's what a 31% move looks like.

Semiconductors had their own soap opera running in the background. Per Barron's midday roundup, Intel fell 1.9% after Elon Musk confirmed that TSMC is in talks with his chip venture Terafab — an awkward headline given that Intel is also a Terafab partner. Nothing like finding out your partner is talking to the other guy, in public, on a Monday. Meanwhile Cerebras went the other way, up 7.6%, after OpenAI CEO Sam Altman posted on social media Friday that the AI-chip startup was a close partner — a public vote of confidence that eased fears Cerebras was losing the high-speed AI chip race to Nvidia. The stock had dropped 15% over the prior five sessions, so the Altman bounce was as much relief as enthusiasm.

Through it all, the bond market kept a hand on the market's shoulder. Yields pressured equities even as tech carried the tape — the 10-year's climb past 5.33% from the morning session is still the macro overhang on everything. That tension is the whole trade right now: AI capex optimism pulling one way, the cost of money pulling the other. So far today, optimism is winning.

What to watch into the close: whether Nvidia can actually print the record, whether RXO's premium holds through the afternoon, and whether yields give back any of the morning's climb. The midday verdict is simple enough — the market wants to go up, and it's letting its best stories drag it there.